Tilt your stock portfolio toward biotech companies now and you could stand to make substantial profits in the near future. You can also find cost-effective stocks under $20 to trade daily on the ...

Just a few months after raising $200 million in third-round financing, immunology specialist Zenas ... acceleration in the number of biotech companies seeking public listings after a two-year ...

The company targets markets in immunology, oncology ... While we acknowledge the potential of biotech companies, our conviction lies in the belief that AI stocks hold greater promise for ...

Biotechnology is a rapidly evolving sector with significant advancements anticipated between 2025 and 2035. As innovations in ...

China is teeming with promising science in areas such as oncology and immunology ... comes not only from other VC firms or even biotech companies. It’s coming from big pharma, he said.

Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting ...

This is not about doing it all but about translating external trends into actionable strategies that keep companies ... the future of biotech The convergence of oncology and immunology is not ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

AbbVie and Anima Biotech have announced that they are collaborating ... that modulate mRNA biology for three targets in cancer and immunology. Anima uses its mRNA Lightning platform to discover ...

A live webcast and archived replay of the Company’s presentation can be accessed under “Events and Presentations” in the Investor & Media Relations section of the Zenas BioPharma website. About Zenas ...